HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnstone, P. A. S. Articles by Amling, C. L. Search for Related Content PubMed PubMed Citation Articles by Johnstone, P. A. S. Articles by Amling, C. L.

Effect of Race on Biochemical Disease-free Outcome in Patients with Prostate Cancer Treated with Definitive Radiation Therapy in an Equal-Access Health Care System: Radiation Oncology Report of the Department of Defense Center for Prostate Disease Research¹

¹ From the Naval Medical Ctr, San Diego, Calif (P.A.S.J., C.J.K., J.D., C.L.A.); Ctr for Prostate Disease Research, Dept of Surgery, Uniformed Service Univ, Bethesda, Md (L.S., H.W., J.W.M., D.G.M.); Walter Reed Army Medical Ctr, Washington, DC (J.W.M., D.G.M.); Naval Medical Ctr, Portsmouth, Va (D.D.M., L.K.); Madigan Army Medical Ctr, Tacoma, Wash (R.L.); National Naval Medical Ctr, Bethesda, Md (R.D., T.D.); Brooke Army Medical Ctr, San Antonio, Tex (M.G.B., J.F.); Malcolm Grow Air Force Medical Ctr, Andrews Air Force Base, Md (D.B.); Eisenhower Army Medical Ctr, Augusta, Ga (D.S.); and the Univ of California, San Diego (P.A.S.J.). From the 2001 RSNA scientific assembly. Received September 6, 2001; revision requested October 2; final revision received April 2, 2002; accepted April 30. Supported by the Ctr for Prostate Disease Research, a program of the Uniformed Services Univ of the Health Sciences administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine and funded by the U.S. Army Medical Research and Materiel Command. Address correspondence to P.A.S.J., Naval Medical Center, San Diego, CA 92134-1014 (e-mail: pajohnstone@nmcsd.med.navy.mil).

View larger version (25K): [in a new window]   Figure 1a. Graphs show that patient race is not associated with biochemical disease-free survival, as stratified according to clinical T stage. (a) For stage T1, the log-rank P value is equal to .24. (b) For stage T2, the log-rank P value is equal to .37. (c) For stage T3, the log-rank P value is equal to .06.

View larger version (23K): [in a new window]   Figure 1b. Graphs show that patient race is not associated with biochemical disease-free survival, as stratified according to clinical T stage. (a) For stage T1, the log-rank P value is equal to .24. (b) For stage T2, the log-rank P value is equal to .37. (c) For stage T3, the log-rank P value is equal to .06.

View larger version (22K): [in a new window]   Figure 1c. Graphs show that patient race is not associated with biochemical disease-free survival, as stratified according to clinical T stage. (a) For stage T1, the log-rank P value is equal to .24. (b) For stage T2, the log-rank P value is equal to .37. (c) For stage T3, the log-rank P value is equal to .06.

View larger version (24K): [in a new window]   Figure 2a. Graphs show that patient race is not associated with biochemical disease-free survival, as stratified according to diagnostic Gleason score. (a) For Gleason score 2-4, the log-rank P value equals .14. (b) For Gleason score 5-7, the log-rank P value equals .14. (c) For Gleason score 8-10, the log-rank P value equals .86.

View larger version (25K): [in a new window]   Figure 2b. Graphs show that patient race is not associated with biochemical disease-free survival, as stratified according to diagnostic Gleason score. (a) For Gleason score 2-4, the log-rank P value equals .14. (b) For Gleason score 5-7, the log-rank P value equals .14. (c) For Gleason score 8-10, the log-rank P value equals .86.

View larger version (24K): [in a new window]   Figure 2c. Graphs show that patient race is not associated with biochemical disease-free survival, as stratified according to diagnostic Gleason score. (a) For Gleason score 2-4, the log-rank P value equals .14. (b) For Gleason score 5-7, the log-rank P value equals .14. (c) For Gleason score 8-10, the log-rank P value equals .86.

View larger version (24K): [in a new window]   Figure 3a. Graphs show that patient race is associated with biochemical disease-free survival only for a diagnostic PSA level greater than 20 ng/mL. (a) For a PSA level less than or equal to 4.0 ng/mL, the log-rank P value equals .84. (b) For a PSA level of 4.1—10.0 ng/mL, the log-rank P value equals .71. (c) For a PSA level of 10.1-20.0 ng/mL, the log-rank P value equals .75. (d) For a PSA level greater than 20.0 ng/mL, the log-rank P value is less than .001.

View larger version (24K): [in a new window]   Figure 3b. Graphs show that patient race is associated with biochemical disease-free survival only for a diagnostic PSA level greater than 20 ng/mL. (a) For a PSA level less than or equal to 4.0 ng/mL, the log-rank P value equals .84. (b) For a PSA level of 4.1—10.0 ng/mL, the log-rank P value equals .71. (c) For a PSA level of 10.1-20.0 ng/mL, the log-rank P value equals .75. (d) For a PSA level greater than 20.0 ng/mL, the log-rank P value is less than .001.

View larger version (25K): [in a new window]   Figure 3c. Graphs show that patient race is associated with biochemical disease-free survival only for a diagnostic PSA level greater than 20 ng/mL. (a) For a PSA level less than or equal to 4.0 ng/mL, the log-rank P value equals .84. (b) For a PSA level of 4.1—10.0 ng/mL, the log-rank P value equals .71. (c) For a PSA level of 10.1-20.0 ng/mL, the log-rank P value equals .75. (d) For a PSA level greater than 20.0 ng/mL, the log-rank P value is less than .001.

View larger version (24K): [in a new window]   Figure 3d. Graphs show that patient race is associated with biochemical disease-free survival only for a diagnostic PSA level greater than 20 ng/mL. (a) For a PSA level less than or equal to 4.0 ng/mL, the log-rank P value equals .84. (b) For a PSA level of 4.1—10.0 ng/mL, the log-rank P value equals .71. (c) For a PSA level of 10.1-20.0 ng/mL, the log-rank P value equals .75. (d) For a PSA level greater than 20.0 ng/mL, the log-rank P value is less than .001.

View larger version (26K): [in a new window]   Figure 4. Graph shows that patient race is associated with the biochemical disease-free survival in the advanced disease group (stage T3-4, Gleason score 8-10, or PSA level greater than 20.0 ng/mL; log-rank P value equal to .017).